Trials / Active Not Recruiting
Active Not RecruitingNCT01676649
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Jewish General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The safety of the combination of ipilimumab with carboplatin/paclitaxel treatment with two different dosing schedules will be investigated in patients with metastatic melanoma. This protocol will also investigate both the clinical benefit of this combination and the features of the host immune system that may predict response to ipilimumab with chemotherapy in patients with unresectable Stage III and Stage IV melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ipilimumab | 3 mg/kg |
| DRUG | Carboplatin | AUC = 6 |
| DRUG | Paclitaxel | 175 mg/m2 |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2017-02-01
- Completion
- 2026-05-01
- First posted
- 2012-08-31
- Last updated
- 2021-02-18
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01676649. Inclusion in this directory is not an endorsement.